In the current environment, pharma must reinvent itself, Schering-Plough's Fred Hassan told Bloomberg yesterday. The Organon acquisition, he says, is the "right move at the right time" (For a brief from MarketWatch, click here). Meanwhile, a recent European market study suggests that the combination asthma drug, indacaterol/mometasone, which Schering codeveloped with Novartis, may become the gold standard for treatment in Europe by 2015, ahead of AstraZeneca's Symbicort, PharmaLive reports. The combination drug is administered once a day. For more on the study, click here.
Bloomberg - (BLOOM)
Mar. 19, 2007. 08:47 PM EST